First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab

Multiple Myeloma (MM)

IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report

Oncol Lett.

Greuter T, Browne M, Dommann-Scherrer C, Binder D, Renner C, Kapp U

doi: 10.3892/ol.2016.5034

Multiple Myeloma (MM)

Rare Differential Diagnosis of Dyspnea: Extramedullary Plasmocytoma (EMP) of the Larynx-Case Report and Review of the Latest Literature of Laryngeal EMP and Laryngeal Involvement of Multiple Myeloma

Case Rep Otolaryngol.

Steinke KV, Schneider BK, Welkoborsky HJ

doi: 10.1155/2019/5654014.

Multiple Myeloma (MM)

Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Semin Oncol Nurs.

Koniarczyk HL, Ferraro C, Miceli T

doi: 10.1016/j.soncn.2017.05.004.

Multiple Myeloma (MM)

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Am J Hematol.

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A

doi: 10.1002/ajh.24781.

Multiple Myeloma (MM)

A phase 1B study of venetoclax combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Multiple Myeloma (MM)

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

J Clin Oncol.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M

doi: 10.1200/

Multiple Myeloma (MM)

Pomalidomide in heavily pretreated refractory multiple myeloma: a case report

Future Oncol.

Palmas A, Piras G, Uras A, Asproni R, Murineddu M, Monne M, Stradoni R, Latte G

doi: 10.2217/fon-2016-0460.

Multiple Myeloma (MM)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Leukemia.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H

doi: 10.1038/leu.2017.122.

COMMENTED

Skin CancerMultiple Myeloma (MM)

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

Hematol Oncol.

Mey UJ, Renner C, von Moos R

doi: 10.1002/hon.2353.

Related content

IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report

Rare Differential Diagnosis of Dyspnea: Extramedullary Plasmocytoma (EMP) of the Larynx-Case Report and Review of the Latest Literature of Laryngeal EMP and Laryngeal Involvement of Multiple Myeloma

Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

A phase 1B study of venetoclax combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Pomalidomide in heavily pretreated refractory multiple myeloma: a case report

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation